MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
July 15 2022 - 8:00AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial
cell-engineering company focused on providing enabling platform
technologies to advance innovative cell-based research as well as
next-generation cell therapeutic discovery, development and
commercialization, today announced that it will release financial
results for the second quarter of 2022 after the U.S. market close
on Wednesday, August 10th, 2022. Company management will host a
conference call to discuss financial results at 4:30 p.m. Eastern
Time.
Conference Call Details
Investors interested in listening to the conference call are
required to register online. It is recommended to register at least
a day in advance. A live and archived webcast of the event will be
available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyteMaxCyte is a
leading commercial cell-engineering company focused on providing
enabling platform technologies to advance innovative cell-based
research as well as next-generation cell therapeutic discovery,
development and commercialization. Over the past 20 years, we
have developed and commercialized our proprietary Flow
Electroporation® platform, which facilitates complex engineering of
a wide variety of cells. Our ExPERT™ platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™ GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1
415-937-5400ir@maxcyte.com |
|
|
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024